A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital
According to the World Health Organisation, migraine is ranked 19th among all diseases causing disability and is the 12th leading cause of years lived with disability among females of all ages worldwide2. Based on the International Headache Society (IHS) guidelines, migraine is classified as episodi...
Gespeichert in:
| Veröffentlicht in: | Research journal of pharmacy and technology 2020, Vol.13 (5), p.2159-2162 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2162 |
|---|---|
| container_issue | 5 |
| container_start_page | 2159 |
| container_title | Research journal of pharmacy and technology |
| container_volume | 13 |
| creator | Koshy, Merin. T. Joseph, Lincy |
| description | According to the World Health Organisation, migraine is ranked 19th among all diseases causing disability and is the 12th leading cause of years lived with disability among females of all ages worldwide2. Based on the International Headache Society (IHS) guidelines, migraine is classified as episodic (EM) or chronic (CM), with CM defined having 15 or more headache days of which at least three months (IHS Classification ICHD-III)1.In addition, health care costs and productivity loss at work were larger in patients with CM than those with EM3. Because of frequent unpleasant and sometimes debilitating side effects, preventive drugs are only prescribed for those migraineurs whose quality of life is significantly adversely affected. The aim of the study is to evaluate comparative effectiveness of Propranolol vs Flunarizine in the prophylactic treatment of migraine Objectives include: 1 The effectiveness of the two antimigraine drugs in reducing the symptoms of migraine. 2 To assess the Quality of life in patients suffering from migraine. 3 Recurrence rate of migraine during study period. 4 To assess the risk factors associated with migraine. 5 To assess the side effects of the drugs MATERIALS AND METHODS: |
| doi_str_mv | 10.5958/0974-360X.2020.00388.1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2430679733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2430679733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c145t-6c1dc70d01817e97082e2205fba15e729fa20a99c29867ffaae8b499e750eaee3</originalsourceid><addsrcrecordid>eNo9kG9Lw0AMxg9RcMx9BTnwdWfu-ufuXo7hnDBRcILvjqxN3Y3a1ms7mJ_edhvLm4TkSZ7wY-xewDQ2sX4Eo6IgTOBrKkHCFCDUeiqu2OgyuL7UQt-ySdPsoI9ExzLSI7af8XdfNTWlrdsT_2i77MCrfGjWHsuqqAqOZcYXRVeid3-uJO5K3m7pKNkeCuw3U77eksf6uPrqvj2edcjX5FuH_sDn6IkveyvXYnHHbnIsGpqc85h9Lp7W82Wwent-mc9WQSqiuA2SVGSpggyEFoqMAi1JSojzDYqYlDQ5SkBjUml0ovIckfQmMoZUDIRE4Zg9nO7WvvrtqGntrup82VtaGYWQKKPCsFclJ1Xao2g85bb27qd_2gqwA2Y7ELQDTTtgtkfMVoT_gWJxXA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430679733</pqid></control><display><type>article</type><title>A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Koshy, Merin. T. ; Joseph, Lincy</creator><creatorcontrib>Koshy, Merin. T. ; Joseph, Lincy</creatorcontrib><description>According to the World Health Organisation, migraine is ranked 19th among all diseases causing disability and is the 12th leading cause of years lived with disability among females of all ages worldwide2. Based on the International Headache Society (IHS) guidelines, migraine is classified as episodic (EM) or chronic (CM), with CM defined having 15 or more headache days of which at least three months (IHS Classification ICHD-III)1.In addition, health care costs and productivity loss at work were larger in patients with CM than those with EM3. Because of frequent unpleasant and sometimes debilitating side effects, preventive drugs are only prescribed for those migraineurs whose quality of life is significantly adversely affected. The aim of the study is to evaluate comparative effectiveness of Propranolol vs Flunarizine in the prophylactic treatment of migraine Objectives include: 1 The effectiveness of the two antimigraine drugs in reducing the symptoms of migraine. 2 To assess the Quality of life in patients suffering from migraine. 3 Recurrence rate of migraine during study period. 4 To assess the risk factors associated with migraine. 5 To assess the side effects of the drugs MATERIALS AND METHODS:</description><identifier>ISSN: 0974-3618</identifier><identifier>EISSN: 0974-360X</identifier><identifier>EISSN: 0974-306X</identifier><identifier>DOI: 10.5958/0974-360X.2020.00388.1</identifier><language>eng</language><publisher>Raipur: A&V Publications</publisher><subject>Anesthesia ; Drugs ; Headaches ; Hospitals ; Migraine ; Pain ; Patients ; Population ; Productivity ; Quality of life ; Risk factors</subject><ispartof>Research journal of pharmacy and technology, 2020, Vol.13 (5), p.2159-2162</ispartof><rights>Copyright A&V Publications May 2020</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids></links><search><creatorcontrib>Koshy, Merin. T.</creatorcontrib><creatorcontrib>Joseph, Lincy</creatorcontrib><title>A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital</title><title>Research journal of pharmacy and technology</title><description>According to the World Health Organisation, migraine is ranked 19th among all diseases causing disability and is the 12th leading cause of years lived with disability among females of all ages worldwide2. Based on the International Headache Society (IHS) guidelines, migraine is classified as episodic (EM) or chronic (CM), with CM defined having 15 or more headache days of which at least three months (IHS Classification ICHD-III)1.In addition, health care costs and productivity loss at work were larger in patients with CM than those with EM3. Because of frequent unpleasant and sometimes debilitating side effects, preventive drugs are only prescribed for those migraineurs whose quality of life is significantly adversely affected. The aim of the study is to evaluate comparative effectiveness of Propranolol vs Flunarizine in the prophylactic treatment of migraine Objectives include: 1 The effectiveness of the two antimigraine drugs in reducing the symptoms of migraine. 2 To assess the Quality of life in patients suffering from migraine. 3 Recurrence rate of migraine during study period. 4 To assess the risk factors associated with migraine. 5 To assess the side effects of the drugs MATERIALS AND METHODS:</description><subject>Anesthesia</subject><subject>Drugs</subject><subject>Headaches</subject><subject>Hospitals</subject><subject>Migraine</subject><subject>Pain</subject><subject>Patients</subject><subject>Population</subject><subject>Productivity</subject><subject>Quality of life</subject><subject>Risk factors</subject><issn>0974-3618</issn><issn>0974-360X</issn><issn>0974-306X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo9kG9Lw0AMxg9RcMx9BTnwdWfu-ufuXo7hnDBRcILvjqxN3Y3a1ms7mJ_edhvLm4TkSZ7wY-xewDQ2sX4Eo6IgTOBrKkHCFCDUeiqu2OgyuL7UQt-ySdPsoI9ExzLSI7af8XdfNTWlrdsT_2i77MCrfGjWHsuqqAqOZcYXRVeid3-uJO5K3m7pKNkeCuw3U77eksf6uPrqvj2edcjX5FuH_sDn6IkveyvXYnHHbnIsGpqc85h9Lp7W82Wwent-mc9WQSqiuA2SVGSpggyEFoqMAi1JSojzDYqYlDQ5SkBjUml0ovIckfQmMoZUDIRE4Zg9nO7WvvrtqGntrup82VtaGYWQKKPCsFclJ1Xao2g85bb27qd_2gqwA2Y7ELQDTTtgtkfMVoT_gWJxXA</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Koshy, Merin. T.</creator><creator>Joseph, Lincy</creator><general>A&V Publications</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04S</scope><scope>04W</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>2020</creationdate><title>A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital</title><author>Koshy, Merin. T. ; Joseph, Lincy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c145t-6c1dc70d01817e97082e2205fba15e729fa20a99c29867ffaae8b499e750eaee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anesthesia</topic><topic>Drugs</topic><topic>Headaches</topic><topic>Hospitals</topic><topic>Migraine</topic><topic>Pain</topic><topic>Patients</topic><topic>Population</topic><topic>Productivity</topic><topic>Quality of life</topic><topic>Risk factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Koshy, Merin. T.</creatorcontrib><creatorcontrib>Joseph, Lincy</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Business</collection><collection>India Database: Science & Technology</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Research journal of pharmacy and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koshy, Merin. T.</au><au>Joseph, Lincy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital</atitle><jtitle>Research journal of pharmacy and technology</jtitle><date>2020</date><risdate>2020</risdate><volume>13</volume><issue>5</issue><spage>2159</spage><epage>2162</epage><pages>2159-2162</pages><issn>0974-3618</issn><eissn>0974-360X</eissn><eissn>0974-306X</eissn><abstract>According to the World Health Organisation, migraine is ranked 19th among all diseases causing disability and is the 12th leading cause of years lived with disability among females of all ages worldwide2. Based on the International Headache Society (IHS) guidelines, migraine is classified as episodic (EM) or chronic (CM), with CM defined having 15 or more headache days of which at least three months (IHS Classification ICHD-III)1.In addition, health care costs and productivity loss at work were larger in patients with CM than those with EM3. Because of frequent unpleasant and sometimes debilitating side effects, preventive drugs are only prescribed for those migraineurs whose quality of life is significantly adversely affected. The aim of the study is to evaluate comparative effectiveness of Propranolol vs Flunarizine in the prophylactic treatment of migraine Objectives include: 1 The effectiveness of the two antimigraine drugs in reducing the symptoms of migraine. 2 To assess the Quality of life in patients suffering from migraine. 3 Recurrence rate of migraine during study period. 4 To assess the risk factors associated with migraine. 5 To assess the side effects of the drugs MATERIALS AND METHODS:</abstract><cop>Raipur</cop><pub>A&V Publications</pub><doi>10.5958/0974-360X.2020.00388.1</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0974-3618 |
| ispartof | Research journal of pharmacy and technology, 2020, Vol.13 (5), p.2159-2162 |
| issn | 0974-3618 0974-360X 0974-306X |
| language | eng |
| recordid | cdi_proquest_journals_2430679733 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Anesthesia Drugs Headaches Hospitals Migraine Pain Patients Population Productivity Quality of life Risk factors |
| title | A Prospective Study of Propranolol and Flunarizine in the Prophylactic Therapy of Migraine in a Tertiary Care Hospital |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A46%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Prospective%20Study%20of%20Propranolol%20and%20Flunarizine%20in%20the%20Prophylactic%20Therapy%20of%20Migraine%20in%20a%20Tertiary%20Care%20Hospital&rft.jtitle=Research%20journal%20of%20pharmacy%20and%20technology&rft.au=Koshy,%20Merin.%20T.&rft.date=2020&rft.volume=13&rft.issue=5&rft.spage=2159&rft.epage=2162&rft.pages=2159-2162&rft.issn=0974-3618&rft.eissn=0974-360X&rft_id=info:doi/10.5958/0974-360X.2020.00388.1&rft_dat=%3Cproquest_cross%3E2430679733%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430679733&rft_id=info:pmid/&rfr_iscdi=true |